| human | Q5 |
| P2798 | Loop ID | 187627 |
| P496 | ORCID iD | 0000-0002-6655-0529 |
| P1153 | Scopus author ID | 7004711695 |
| P108 | employer | University of Sydney | Q487556 |
| P735 | given name | Michael | Q4927524 |
| Michael | Q4927524 | ||
| P106 | occupation | chemist | Q593644 |
| P21 | sex or gender | male | Q6581097 |
| Q50106694 | A patent review of oxytocin receptor antagonists 2013-2017. |
| Q51420967 | A systematic exploration of the effects of flexibility and basicity on sigma (σ) receptor binding in a series of substituted diamines. |
| Q48020201 | Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. |
| Q34038251 | Altered proteostasis in aging and heat shock response in C. elegans revealed by analysis of the global and de novo synthesized proteome |
| Q48330042 | Amyloid load and translocator protein 18 kDa in APPswePS1-dE9 mice: a longitudinal study. |
| Q48578686 | Bio-orthogonal labeling as a tool to visualize and identify newly synthesized proteins in Caenorhabditis elegans |
| Q34410718 | Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non-peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study in rats. |
| Q35132428 | Brain inflammation is induced by co-morbidities and risk factors for stroke |
| Q57173432 | Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors |
| Q39535676 | Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats |
| Q47415741 | Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors. |
| Q89743808 | Correction to Synthesis of Usnic Acid Derivatives and Evaluation of Their Antiproliferative Activity against Cancer Cells |
| Q33830420 | Could (18) F-DPA-714 PET imaging be interesting to use in the early post-stroke period? |
| Q57160152 | Cubanes in Medicinal Chemistry |
| Q38386156 | DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications |
| Q36141704 | Derivatives of the pyrazolo[1,5-a]pyrimidine acetamide DPA-713 as translocator protein (TSPO) ligands and pro-apoptotic agents in human glioblastoma |
| Q42128503 | Detection of Neuroinflammation in a Rat Model of Subarachnoid Hemorrhage Using [18F]DPA-714 PET Imaging |
| Q38858777 | Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples |
| Q90949126 | Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination |
| Q112278108 | Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant |
| Q53387482 | Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists. |
| Q47401446 | Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia |
| Q34474069 | Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. |
| Q58027784 | Erratum: Corrigendum: Bio-orthogonal labeling as a tool to visualize and identify newly synthesized proteins in Caenorhabditis elegans |
| Q38905206 | Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO). |
| Q38828341 | First Demonstration of Positive Allosteric-like Modulation at the Human Wild Type Translocator Protein (TSPO). |
| Q92660171 | First Nondiscriminating Translocator Protein Ligands Produced from a Carbazole Scaffold |
| Q87033994 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors |
| Q90409201 | Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases |
| Q55058116 | Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation. |
| Q60043974 | Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [C]DPA-713 PET |
| Q33892289 | Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players. |
| Q92617059 | In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors |
| Q59340739 | In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [F]DPA714 PET |
| Q36915357 | In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma |
| Q38684872 | Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration |
| Q46365626 | Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists |
| Q48661773 | Investigations of amide bond variation and biaryl modification in analogues of α7 nAChR agonist SEN12333. |
| Q38760031 | Kinase targets in CNS drug discovery. |
| Q36070781 | Lack of neuroinflammation in the HIV-1 transgenic rat: an [(18)F]-DPA714 PET imaging study |
| Q48327909 | Longitudinal investigation of neuroinflammation and metabolite profiles in the APPswe ×PS1Δe9 transgenic mouse model of Alzheimer's disease |
| Q90803891 | Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists |
| Q50132447 | MDMA ('Ecstasy'), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors |
| Q39088915 | Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology |
| Q34975182 | N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as σ receptor ligands with potential neuroprotective effects. |
| Q48635249 | Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [11C]DPA-713 positron emission tomography |
| Q28392661 | Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study |
| Q93092456 | O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease |
| Q43231855 | Oxo-bridged isomers of aza-trishomocubane sigma (sigma) receptor ligands: Synthesis, in vitro binding, and molecular modeling |
| Q88757739 | Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease |
| Q48175001 | Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X7 Receptor Antagonist. |
| Q87831251 | Pharmacological evaluation of a novel series of urea, thiourea and guanidine derivatives as P2X7 receptor antagonists |
| Q46024062 | Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues. |
| Q34483203 | Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. |
| Q34534266 | Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues |
| Q38823372 | Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling |
| Q33767010 | Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis |
| Q48141154 | Rapid access to N-(indol-2-yl)amides and N-(indol-3-yl)amides as unexplored pharmacophores |
| Q33834306 | Regional brain distribution of translocator protein using [(11)C]DPA-713 PET in individuals infected with HIV. |
| Q58121443 | Remarkable Enhancement in Boron Uptake Within Glioblastoma Cells With Carboranyl-Indole Carboxamides |
| Q90949988 | Ring-opened aminothienopyridazines as novel tau aggregation inhibitors |
| Q36282217 | Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma. |
| Q50744095 | Structure-activity relationship studies of SEN12333 analogues: determination of the optimal requirements for binding affinities at α7 nAChRs through incorporation of known structural motifs. |
| Q53640932 | Structure-activity relationships of N-substituted 4-(trifluoromethoxy)benzamidines with affinity for GluN2B-containing NMDA receptors. |
| Q58428304 | Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues |
| Q46820382 | Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA. |
| Q59291869 | Synthesis and Radiolabelling of Ipratropium and Tiotropium for Use as PET Ligands in the Study of Inhaled Drug Deposition |
| Q58600404 | Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A |
| Q91876088 | Synthesis and in vitro evaluation of fluorine-18 benzimidazole sulfones as CB2 PET-radioligands |
| Q91699439 | Synthesis of Usnic Acid Derivatives and Evaluation of Their Antiproliferative Activity against Cancer Cells |
| Q38628888 | TSPO as a target for glioblastoma therapeutics |
| Q90225695 | Targeting the Oxytocin System: New Pharmacotherapeutic Approaches |
| Q37146954 | The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities |
| Q89395599 | The Formation of Seven-Membered Heterocycles under Mild Pictet-Spengler Conditions: A Route to Pyrazolo[3,4]benzodiazepines |
| Q48050302 | The Polyphenol Altenusin Inhibits in Vitro Fibrillization of Tau and Reduces Induced Tau Pathology in Primary Neurons |
| Q38714443 | The Recent Development of α7 Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases. |
| Q48208817 | The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogues |
| Q50950028 | The development of CNS-active LRRK2 inhibitors using property-directed optimisation. |
| Q38166977 | The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET). |
| Q38201104 | The first CNS-active carborane: A novel P2X7 receptor antagonist with antidepressant activity. |
| Q34336690 | The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse |
| Q38560778 | The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia |
| Q38091851 | The translocator protein (TSPO): a novel target for cancer chemotherapy. |
| Q38195637 | The translocator protein as a drug target in Alzheimer's disease. |
| Q40369760 | Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia |
| Q50596635 | WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action. |
| Q27314677 | [18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in rats |
| Q53068160 | [18F]DPA-C5yne, a novel fluorine-18-labelled analogue of DPA-714: radiosynthesis and preliminary evaluation as a radiotracer for imaging neuroinflammation with PET. |
Search more.